Post by Future Market Insights, Inc.

After the Semaglutide Patent Cliff: Where India’s New GLP-1 Supply Will Go Semaglutide’s India patent cliff has not created a simple “generic launch” story. It has triggered a broader industrial race across peptide chemistry, drug-device manufacturing, specialist prescription channels, cold-chain logistics, pharmacovigilance and export registration. The first destination is clearly India. The second is not “the world,” but a selective set of jurisdictions where patent freedom, regulatory approval, device supply and local market access line up. The evidence is unusually visible. https://lnkd.in/g9Qdq4r4